Type
|
Public |
---|---|
Traded as | NYSE: ABC S&P 500 Component |
Industry | Pharmaceutical |
Founded | Merger between AmeriSource Health and Bergen Brunswig in 2001 |
Headquarters | Conshohocken, Pennsylvania, U.S. |
Area served
|
North America United Kingdom |
Key people
|
Richard C. Gozon (Chairman) Steven H. Collis (President), (CEO) & (Director) |
Products | Pharmaceuticals and pharmacy services |
Revenue | US$135.9 billion (2015) |
Operating income
|
US$386 million (2015) |
Net income
|
US$-134 million (2015) |
Total assets | US$27.73 billion (2015) |
Total equity | US$633 million (2015) |
Number of employees
|
16,500 (2015) |
Website | AmerisourceBergen.com |
AmerisourceBergen Corporation is an American drug wholesale company that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. They provide drug distribution and related services designed to reduce costs and improve patient outcomes, distribute a line of brand name and generic pharmaceuticals, over-the-counter (OTC) health care products and home health care supplies and equipment to a wide variety of health care providers located throughout the United States, including acute care hospitals and health systems, independent and chain retail pharmacies, mail-order facilities, physicians, clinics and other alternate site facilities, as well as skilled nursing and assisted living centers. They also provide pharmaceuticals and pharmacy services to long-term care, workers' compensation and specialty drug patients.
AmerisourceBergen is a market leader in pharmaceutical distribution handling about 20% of all of the pharmaceuticals sold and distributed throughout the country and ranked 16th on the Fortune 500 list for 2015 with over $100 Billion in annual revenue. In terms of revenue (79.49 billion in 2012) the firm is the largest based in Pennsylvania.
AmerisourceBergen was formed in 2001 following the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation. AmeriSource and Bergen were both successful pharmaceutical distributors that served similar markets but covered somewhat different geographies. Bringing the two together gave the company a strong national presence that was geared especially towards serving independent community pharmacies, regional retail chain pharmacies, hospitals, physician offices, clinics and other alternate care facilities.
AmerisourceBergen has 26 pharmaceutical distribution centers in the US, nine distribution centers in Canada, four specialty distribution centers in the US, and over 1 million square feet of packaging production capacity in the US and the UK. With the addition of World Courier, the largest specialty courier company in the world, over 150 company-owned offices around the globe were added to the company.
In 2012 the state of West Virginia filed a lawsuit against AmerisourceBergen On 5/17/2015, the West Virginia Gazette reported, "AmerisourceBergen, the nation’s third largest drug wholesaler, shipped 80.3 million hydrocodone pills and 38.4 million oxycodone pills to West Virginia over the five-year span — the highest totals for both drugs by any company named in the state’s lawsuit, according to the filing. and that "The lawsuit alleges that the companies have helped fuel the state’s pain pill epidemic by shipping excessive amounts of prescription painkillers to southern West Virginia pharmacies."
AmerisourceBergen operates its pharmaceutical distribution business under four primary units: AmerisourceBergen Drug Corporation (ABDC), AmerisourceBergen Specialty Group (ABSG), AmerisourceBergen Consulting Services (ABCS) and World Courier. In March 2016 Walgreens Boots Alliance Inc. announced it would exercise an option to purchase 22.7 million shares of AmerisourceBergen stock and thereby control 15% of the company.
Good Neighbor Pharmacy is an American retailers' cooperative network of more than 3,400 independently owned and operated pharmacies. It has a business affiliation with AmerisourceBergen, which sponsors the network and owns the name "Good Neighbor Pharmacy" Good Neighbor Pharmacy is the sponsor for "Thought Spot" the annual trade show held in Las Vegas.
ThoughtSpot is a four-day trade show put on by Good Neighbor Pharmacy held in or around July in Las Vegas aimed for and limited to community and independent pharmacies.
Exhibitors are represented throughout the healthcare industry including, brand name, generic and over the counter products. ThoughtSpot 2013 was hosted at the MGM Grand, Las Vegas from July 24 to July 27. Special guest musical performance by Bret Michaels capped off the week on July 27 at a special attendee-only closing event.
KnowledgeDriven is a resource site sponsored by AmerisourceBergen.
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q4 2022 | 2022-11-03 | 2.60 | 2.60 |
Q3 2022 | 2022-08-03 | 2.62 | 2.62 |
Q2 2022 | 2022-05-04 | 3.22 | 3.22 |
Q1 2022 | 2022-02-02 | 2.58 | 2.58 |
Q4 2021 | 2021-11-04 | 2.39 | 2.39 |
Q3 2021 | 2021-08-04 | 2.16 | 2.16 |
Q2 2021 | 2021-05-05 | 2.53 | 2.53 |
Q1 2021 | 2021-02-04 | 2.18 | 2.18 |
Q4 2020 | 2020-11-05 | 1.89 | 1.89 |
Q3 2020 | 2020-08-05 | 1.85 | 1.85 |
2016-06-07 | Reiterated Rating | Bank of America | Neutral | |
2016-06-07 | Reiterated Rating | Bank of America Corp. | Neutral | |
2016-06-04 | Reiterated Rating | Argus | Buy | |
2016-06-01 | Downgrade | Raymond James | Outperform to Market Perform | |
2016-06-01 | Downgrade | Raymond James Financial Inc. | Outperform to Market Perform | |
2016-05-06 | Boost Price Target | RBC Capital | Outperform | $85.00 to $100.00 |
2016-05-06 | Lower Price Target | FBR & Co. | Market Perform | $100.00 to $84.00 |
2016-05-06 | Reiterated Rating | Robert W. Baird | Hold | |
2016-05-06 | Boost Price Target | Royal Bank Of Canada | Outperform | $85.00 to $100.00 |
2016-05-06 | Lower Price Target | FBR & Co | Market Perform | $100.00 to $84.00 |
2016-05-05 | Downgrade | Avondale Partners | Outperform to Market Perform | |
2016-04-18 | Initiated Coverage | Avondale Partners | Outperform | $111.00 |
2016-03-15 | Initiated Coverage | Credit Suisse | Outperform | $103.00 |
2016-03-15 | Boost Price Target | Cowen and Company | $95.00 to $98.00 | |
2016-03-15 | Initiated Coverage | Credit Suisse Group AG | Outperform | $103.00 |
2016-02-06 | Reiterated Rating | Barclays | Hold | |
2016-02-06 | Reiterated Rating | Barclays PLC | Hold | |
2016-02-05 | Lower Price Target | Robert W. Baird | Equal Weight to Neutral | $108.00 to $99.00 |
2016-02-05 | Reiterated Rating | Deutsche Bank | Hold | $103.00 to $96.00 |
2016-02-05 | Lower Price Target | Barclays | Equal Weight | $100.00 to $90.00 |
2016-02-05 | Lower Price Target | RBC Capital | Outperform | $120.00 to $100.00 |
2016-02-05 | Reiterated Rating | Deutsche Bank AG | Hold | $103.00 to $96.00 |
2016-02-04 | Lower Price Target | FBR & Co. | Mkt Perform | $110.00 to $100.00 |
2016-01-29 | Lower Price Target | Leerink Swann | Outperform | $129.00 to $105.00 |
2016-01-27 | Lower Price Target | Deutsche Bank | Hold | $109.00 to $103.00 |
2016-01-12 | Reiterated Rating | Robert W. Baird | Neutral | $113.00 to $108.00 |
2016-01-06 | Downgrade | Raymond James | Outperform to Market Perform | |
2015-11-18 | Lower Price Target | Mizuho | Neutral | $112.00 to $105.00 |
2015-11-17 | Initiated Coverage | Credit Suisse | Outperform | $121.00 |
2015-11-16 | Upgrade | Morgan Stanley | Underweight to Equal Weight | |
2015-11-01 | Reiterated Rating | Deutsche Bank | Hold | $109.00 |
2015-10-30 | Boost Price Target | Cowen and Company | $107.00 to $109.00 | |
2015-10-30 | Lower Price Target | Robert W. Baird | $115.00 to $113.00 | |
2015-10-21 | Lower Price Target | Cowen and Company | $119.00 to $107.00 | |
2015-10-12 | Reiterated Rating | Deutsche Bank | Hold | $106.00 |
2015-10-07 | Lower Price Target | Raymond James | Outperform | $130.00 to $110.00 |
2015-10-07 | Reiterated Rating | Evercore ISI | Hold | |
2015-10-07 | Reiterated Rating | RBC Capital | Outperform | $130.00 |
2015-10-06 | Reiterated Rating | Cowen and Company | Hold | |
2015-10-02 | Downgrade | Morgan Stanley | Equal Weight to Underweight | $120.00 to $93.00 |
2015-07-16 | Boost Price Target | KeyBanc | Overweight | $61.00 to $63.00 |
2015-07-16 | Boost Price Target | KeyCorp | Overweight | $61.00 to $63.00 |
2015-05-18 | Downgrade | Cowen and Company | Outperform to Market Perform | $121.00 |
2015-05-13 | Boost Price Target | Argus | Buy | $104.00 to $135.00 |
2015-05-01 | Boost Price Target | Barclays | Equal Weight | $90.00 to $93.00 |
2015-05-01 | Boost Price Target | RBC Capital | Outperform | $120.00 to $130.00 |
2015-05-01 | Boost Price Target | FBR & Co. | Market Perform | $108.00 to $115.00 |
2015-05-01 | Boost Price Target | Mizuho | Buy | $110.00 to $112.00 |
2015-04-23 | Boost Price Target | RBC Capital | Outperform | $110.00 to $120.00 |
2015-03-20 | Boost Price Target | FBR & Co. | Hold | $100.00 to $108.00 |
2015-03-13 | Reiterated Rating | Mizuho | Hold | $94.00 to $110.00 |
2015-03-03 | Boost Price Target | RBC Capital | Outperform | $106.00 to $110.00 |
2015-01-29 | Boost Price Target | Deutsche Bank | Hold | $89.00 to $96.00 |
2015-01-29 | Boost Price Target | Credit Suisse | Outperform | $95.00 to $108.00 |
2015-01-29 | Boost Price Target | RBC Capital | Outperform | $95.00 to $106.00 |
2015-01-29 | Boost Price Target | FBR & Co. | Market Perform | $90.00 to $100.00 |
2015-01-29 | Boost Price Target | Mizuho | Neutral | $87.00 to $94.00 |
2015-01-13 | Boost Price Target | Cowen and Company | Outperform | $93.00 to $100.00 |
2015-01-08 | Reiterated Rating | JPMorgan Chase & Co. | Hold | $89.00 to $92.00 |
2015-01-08 | Downgrade | Barclays | Overweight to Equal Weight | $89.00 to $90.00 |
2014-11-21 | Downgrade | FBR & Co. | Outperform to Market Perform | $90.00 |
2014-11-04 | Reiterated Rating | Credit Suisse | Outperform | $83.00 to $95.00 |
2014-10-31 | Boost Price Target | Mizuho | Neutral | $75.00 to $87.00 |
2014-10-31 | Downgrade | ISI Group | Strong Buy to Buy | $89 |
2014-10-31 | Reiterated Rating | Barclays | Overweight | $83.00 to $89.00 |
2014-10-31 | Reiterated Rating | Deutsche Bank | Hold | $80.00 to $86.00 |
2014-10-31 | Reiterated Rating | FBR & Co. | Outperform | $83.00 to $90.00 |
2014-10-31 | Reiterated Rating | Citigroup Inc. | Buy | $89.00 to $98.00 |
2014-10-31 | Boost Price Target | Cowen and Company | Outperform | $85.00 to $93.00 |
2014-10-31 | Boost Price Target | RBC Capital | Outperform | $88.00 to $95.00 |
2014-10-31 | Downgrade | Evercore ISI | Strong-Buy to Buy | $89.00 |
2014-10-16 | Initiated Coverage | RBC Capital | Outperform | $88.00 |
2014-07-25 | Reiterated Rating | S&P Equity Research | Strong-Buy | |
2014-07-25 | Reiterated Rating | Raymond James | Outperform | $74.00 to $85.00 |
2014-07-25 | Reiterated Rating | Deutsche Bank | Hold | $73.00 to $80.00 |
2014-07-25 | Reiterated Rating | Citigroup Inc. | Buy | $83.00 to $89.00 |
2014-07-25 | Reiterated Rating | Barclays | Overweight | $77.00 to $83.00 |
2014-07-25 | Boost Price Target | FBR & Co. | Outperform | $75.00 to $83.00 |
2014-07-24 | Boost Price Target | Mizuho | Neutral | $72.00 to $75.00 |
2014-07-10 | Boost Price Target | Robert W. Baird | Neutral | $70.00 to $74.00 |
2014-04-25 | Reiterated Rating | Deutsche Bank | Hold | $73.00 |
2014-04-25 | Lower Price Target | Cowen and Company | $80.00 to $75.00 | |
2014-04-25 | Lower Price Target | Raymond James | $79.00 to $74.00 | |
2014-04-24 | Lower Price Target | Mizuho | Neutral | $75.00 to $72.00 |
2014-04-10 | Upgrade | FBR Capital | Mkt Perform to Outperform | $75 |
2014-04-10 | Upgrade | Evercore ISI | Neutral to Buy | $74.00 |
2014-04-09 | Resumed | FBR Capital | Outperform | $75 |
2014-04-09 | Upgrade | FBR & Co. | Market Perform to Outperform | $75.00 |
2014-03-12 | Downgrade | Goldman Sachs | Buy to Neutral | $78.00 to $75.00 |
2014-03-05 | Initiated Coverage | Barclays | Overweight | $77.00 |
2014-02-18 | Initiated Coverage | Citigroup Inc. | Hold to Buy | |
2014-01-24 | Boost Price Target | Argus | Buy | $73.00 to $83.00 |
2014-01-24 | Boost Price Target | Raymond James | $73.00 to $79.00 | |
2014-01-24 | Boost Price Target | FBR & Co. | Market Perform | $72.00 to $75.00 |
2013-12-17 | Boost Price Target | Deutsche Bank | Buy | $72.00 to $78.00 |
2013-11-20 | Initiated Coverage | Deutsche Bank | Hold | $75.00 |
2013-11-08 | Boost Price Target | Argus | Buy | $65.00 to $73.00 |
2013-11-04 | Boost Price Target | Mizuho | Neutral | $57.00 to $67.00 |
2013-11-01 | Reiterated | UBS | Neutral | $57 to $67 |
2013-11-01 | Boost Price Target | Raymond James | Outperform | $63.00 to $73.00 |
2013-11-01 | Boost Price Target | Credit Suisse | Outperform | $65.00 to $73.00 |
2013-11-01 | Boost Price Target | Cowen and Company | Outperform | $69.00 to $78.00 |
2013-10-29 | Initiated | FBR Capital | Mkt Perform | $72 |
2013-10-29 | Initiated Coverage | FBR & Co. | Market Perform | $72.00 |
2013-10-15 | Boost Price Target | Robert W. Baird | Neutral | $57.00 to $61.00 |
2013-10-14 | Boost Price Target | Evercore ISI | Neutral | $59.00 to $65.00 |
2013-09-18 | Initiated Coverage | Sterne Agee CRT | Buy | $80.00 |
2013-07-15 | Reiterated | Mizuho | Neutral | $45 to $57 |
2013-04-26 | Reiterated | ISI Group | Neutral | $54 to $58 |
2013-04-26 | Downgrade | Robert W. Baird | Outperform to Neutral | $59 to $57 |
2013-03-20 | Reiterated | Argus | Buy | $50 to $60 |
2013-03-20 | Downgrade | ISI Group | Buy to Neutral | $54 |
2013-03-18 | Downgrade | UBS | Buy to Neutral | |
2013-03-05 | Downgrade | ISI Group | Strong Buy to Buy | $51.50 to $53 |
2013-01-23 | Reiterated | UBS | Buy | $45 to $51 |
2013-01-04 | Downgrade | Mizuho | Buy to Neutral | $45 |
2016-06-07 | Reiterated Rating | Bank of America | Neutral | |
2016-06-07 | Reiterated Rating | Bank of America Corp. | Neutral | |
2016-06-04 | Reiterated Rating | Argus | Buy | |
2016-06-01 | Downgrade | Raymond James | Outperform to Market Perform | |
2016-06-01 | Downgrade | Raymond James Financial Inc. | Outperform to Market Perform |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ABC 605 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
Vanguard Group, Inc | 19.22M |
BlackRock Inc. | 16.84M |
JPMORGAN CHASE & CO | 7.35M |
STATE STREET CORP | 6.99M |
BlackRock Institutional Trust Company, N.A. | 5.51M |
FMR LLC | 5.45M |
Boston Partners | 5.04M |
Invesco Ltd. | 3.76M |
GEODE CAPITAL MANAGEMENT, LLC | 3.09M |
BlackRock Fund Advisors | 3.08M |
FIL Ltd | 2.35M |
MORGAN STANLEY | 2.24M |
BlackRock Group LTD | 2.24M |
NORTHERN TRUST CORP | 2.01M |
WELLS FARGO & CO/MN | 1.73M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
Walgreens Boots Alliance, Inc. | 14.85% (34157955) | ABC / WBA / |
COLLIS STEVEN H President & CEO | 0.12% (266575) | ABC / THOR / |
GOZON RICHARD C | 0.02% (51484) | ABC / TGI / |
Chou John G. Executive Vice President | 0.02% (51288) | ABC / |
Guttman Tim G. Chief Financial Officer | 0.02% (50671) | ABC / |
Howell Peyton R Senior Vice President | 0.02% (47989) | ABC / |
Frary James Senior Vice President | 0.02% (38755) | ABC / |
LONG MICHAEL J | 0.02% (34685) | ABC / ARW / |
COTROS CHARLES H | 0.01% (26773) | ABC / |
HENNEY JANE E MD | 0.01% (15045) | ABC / CBST / CI / |
Clark Gina Executive Vice President | 0.01% (13614) | ABC / |
GOCHNAUER RICHARD W | 0.01% (13225) | ABC / UGI / |
McGee Henry Wadsworth III | 0.01% (12719) | ABC / GCI / |
Mauch Robert P. Executive Vice President | 0.01% (12123) | ABC / |